Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab

Modern Rheumatology

Volumn 19, Issue 1, 2009, Pages 42-46

  Nakajima, Shoko ^a   Naruto, Takuya ^a   Miyamae, Takako ^a   Imagawa, Tomoyuki ^a   Mori, Masaaki ^a   Nishimaki, Shigeru ^a   Yokota, Shumpei ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Anti IL 6 receptor monoclonal antibody; Cartilage oligomeric matrix protein (COMP); Growth impairment; Interleukin 6 (IL 6); Systemic idiopathic juvenile arthritis (sJIA)

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ATLIZUMAB; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; STROMELYSIN;

ARTICLE; BONE REMODELING; BONE TURNOVER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GROWTH DISORDER; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GLYCOPROTEINS; HUMANS; INFANT; MALE; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME;

EID: 60149104218     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-008-0115-3     Document Type: Article

References (24)

1. Briggs MD, Hoffman SM, King LM, Olsen AS, Mohrenweiser H, Leroy JG, et al. Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene. Nat Genet. 1995;10:330-6.
2. Deere M, Sanford T, Francomano CA, Daniels K, Hecht JT. Identification of nine novel mutations in cartilage oligomeric matrix protein in patients with pseudoachondroplasia and multiple epiphyseal dysplasia. Am J Med Genet. 1999;85:486-90.
3. Mabuchi A, Haga N, Ikeda T, Manabe N, Ohashi H, Takatori Y, et al. Novel mutation in exon 18 of the cartilage oligomeric matrix protein gene causes a severe pseudoachondroplasia. Am J Med Genet. 2001;104:135-9.
4. Briggs MD, Chapman KL. Pseudoachondroplasia and multiple epiphyseal dysplasia: Mutation review, molecular interactions, and genotype to phenotype correlations. Hum Mutat. 2002;19:465-78.
5. Mabuchi A, Manabe N, Haga N, Kitoh H, Ikeda T, Kawaji H, et al. Novel types of COMP mutations and genotype-phenotype association in pseudoachondroplasia and multiple epiphyseal dysplasia. Hum Genet. 2003;112:84-90.
6. Recklies AD, Baillargeon L, White C. Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. Arthritis Rheum. 1998;41:997-1006.
7. Dragomir AD, Kraus VB, Renner JB, Luta G, Clark A, Vilim V, et al. Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology. Osteoarthritis Cartilage. 2002;10:687-91.
8. Vilim V, Olejarova M, Machacek S, Gatterova J, Kraus VB, Pavelka K. Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage. 2002;10:707-13.
9. Vilim V, Vytasek R, Olejarova M, Machacek S, Gatterova J, Prochazka B, et al. Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage. 2001;9:612-8.
10. Skoumal M, Kolarz G, Klingler A. Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis. Scand J Rheumatol. 2003;32:156-61.
11. Urakami T, Manki A, Inoue T, Oda M, Tanaka H, Morishima T. Clinical significance of decreased serum concentration of cartilage oligomeric matrix protein in systemic juvenile idiopathic arthritis. J Rheumatol. 2006;33:996-1000.
12. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M. Inflammatory cytokines and systemic-onset juvenile idiopathic arthritis. Mod Rheumatol. 2004;14:12-7.
13. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:818-25.
14. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998-1006.
15. Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2005;28:231-8.
16. Nishimoto N, Kishimoto T. Interleukin 6: From bench to bedside. Nat Clin Pract Rheumatol. 2006;2:619-26.
17. Petty RE. Classification of childhood arthritis: A work in progress. Baillieres Clin Rheumatol. 1998;12:181-90.
18. Wagner E, Ammer K, Kolarz G, Krajnc I, Palkonyai E, Scherak O, et al. Predicting factors for severity of rheumatoid arthritis: A prospective multicenter cohort study of 172 patients over 3 years. Rheumatol Int. 2007;27:1041-8.
19. Saxne T, Heinegard D. Cartilage oligomeric matrix protein: A novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol. 1992;31:583-91.
20. Spitznagel L, Nitsche DP, Paulsson M, Maurer P, Zaucke F. Characterization of a pseudoachondroplasia-associated mutation (His587 → Arg) in the C-terminal, collagen-binding domain of cartilage oligomeric matrix protein (COMP). Biochem J. 2004;377:479-87.
21. Bjarnason R, Andersson B, Kim HS, Olsson B, Swolin-Eide D, Wickelgren R, et al. Cartilage oligomeric matrix protein increases in serum after the start of growth hormone treatment in prepubertal children. J Clin Endocrinol Metab. 2004;89:5156-60.
22. Sugiyama E. Role of matrix metalloproteinase-3 in joint destruction in rheumatoid arthritis. Clin Calcium. 2007;17:528-34.
23. Pagani F, Francucci CM, Moro L. Markers of bone turnover: Biochemical and clinical perspectives. J Endocrinol Invest. 2005;28:8-13.
24. Camozzi V, Tossi A, Simoni E, Pagani F, Francucci CM, Moro L. Role of biochemical markers of bone remodeling in clinical practice. J Endocrinol Invest. 2007;30:13-7.